Clinical Evidence behind Stereotactic Radiotherapy for the Treatment of Ventricular Tachycardia (STAR)-A Comprehensive Review

The electrophysiology-guided noninvasive cardiac radioablation, also known as STAR (stereotactic arrhythmia radioablation) is an emerging treatment method for persistent ventricular tachycardia. Since its first application in 2012 in Stanford Cancer Institute, and a year later in University Hospital Ostrava, Czech Republic, the authors from all around the world have published case reports and case series, and several prospective trials were established. In this article, we would like to discuss the available clinical evidence, analyze the potentially clinically relevant differences in methodology, and address some of the unique challenges that come with this treatment method.

Automated summary

STAR, also known as stereotactic arrhythmia radioablation, is an emerging noninvasive treatment method for persistent ventricular tachycardia. Since its first application in 2012 at Stanford Cancer Institute, and subsequently at University Hospital Ostrava, Czech Republic, authors worldwide have published case reports and established prospective trials. This article discusses the available clinical evidence, analyzes potential methodological differences, and addresses unique challenges associated with this treatment approach.